Predictors of early recurrence of oesophagogastric adenocarcinoma after neoadjuvant FLOT
-
Published:2024-12
Issue:12
Volume:50
Page:108657
-
ISSN:0748-7983
-
Container-title:European Journal of Surgical Oncology
-
language:en
-
Short-container-title:European Journal of Surgical Oncology
Author:
Dayanamby AbbienayaORCID,
Chmelo Jakub,
Bradshaw Alexander,
Phillips Alexander W.ORCID
Reference22 articles.
1. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
2. Pattern of recurrence and patient survival after perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) for locally advanced esophagogastric adenocarcinoma in patients treated outside clinical trials;Glatz;J Clin Med,2020
3. Machine learning to predict early recurrence after oesophageal cancer surgery;Rahman;Br J Surg,2020
4. Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution;Lombardi;Updates Surg,2023
5. Advances in the curative management of oesophageal cancer;Bolger;Br J Cancer,2022